Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas.
Paul A. Christensen,Randall J. Olsen,S. Wesley Long,Sishir Subedi,James J. Davis,Parsa Hodjat,Debbie R. Walley,Jacob C. Kinskey,Matthew Ojeda Saavedra,Layne Pruitt,Kristina Reppond,Madison N. Shyer,Jessica Cambric,Ryan Gadd,Rashi M. Thakur,Akanksha Batajoo,Regan Mangham,Sindy Pena,Trina Trinh,Prasanti Yerramilli,Marcus Nguyen,Robert Olson,Richard Snehal,Jimmy Gollihar,James M. Musser +24 more
Reads0
Chats0
TLDR
In this paper, the authors sequenced the genomes of 16,965 SARS-CoV-2 from samples acquired March 15, 2021 through September 20, 2021 in the Houston Methodist hospital system.Abstract:
Genetic variants of SARS-CoV-2 have repeatedly altered the course of the COVID-19 pandemic. Delta variants of concern are now the focus of intense international attention because they are causing widespread COVID-19 disease globally and are associated with vaccine breakthrough cases. We sequenced the genomes of 16,965 SARS-CoV-2 from samples acquired March 15, 2021 through September 20, 2021 in the Houston Methodist hospital system. This sample represents 91% of all Methodist system COVID-19 patients during the study period. Delta variants increased rapidly from late April onward to cause 99.9% of all COVID-19 cases and spread throughout the Houston metroplex. Compared to all other variants combined, Delta caused a significantly higher rate of vaccine breakthrough cases (23.7% for Delta compared to 6.6% for all other variants combined). Importantly, significantly fewer fully vaccinated individuals required hospitalization. Individuals with vaccine breakthrough cases caused by Delta had a low median PCR cycle threshold (Ct) value (a proxy for high virus load). This value was closely similar to the median Ct value for unvaccinated patients with COVID-19 caused by Delta variants, suggesting that fully vaccinated individuals can transmit SARS-CoV-2 to others. Patients infected with Alpha and Delta variants had several significant differences. Our integrated analysis emphasizes that vaccines used in the United States are highly effective in decreasing severe COVID-19 disease, hospitalizations, and deaths.read more
Citations
More filters
Journal ArticleDOI
Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas
Paul A. Christensen,Randall J. Olsen,S. Wesley Long,R. D. Snehal,James J. Davis,Matthew Ojeda Saavedra,K. Reppond,Madison N. Shyer,Jessica E. Cambric,Ryan D. H. Gadd,R. M. Thakur,A. Batajoo,R. Mangham,S Silva Peña,Tri Quang Trinh,Jacob C. Kinskey,Guy Williams,Robert Olson,Jimmy Gollihar,James M. Musser +19 more
TL;DR: In this article , a genome sequencing study of SARS-CoV-2 in the Houston Methodist health care system identified 4468 symptomatic patients with infections caused by Omicron (B.1.529) from late November 2021 through January 5, 2022.
Journal ArticleDOI
Multiple spillovers from humans and onward transmission of SARS-CoV-2 in white-tailed deer
Suresh V. Kuchipudi,Meera Surendran-Nair,Rachel Ruden,Michèle Gan Yon,Ruth H. Nissly,Kurt J. Vandegrift,Rahul K. Nelli,Lingling Li,Bhushan M. Jayarao,Costas D. Maranas,Nicole Levine,Katriina Willgert,Andrew J. K. Conlan,Randall J. Olsen,James J. Davis,James M. Musser,Peter J. Hudson,Vivek Kapur +17 more
TL;DR: The discovery of widespread infection of white-tailed deer indicates their establishment as potential reservoir hosts for SARS-CoV-2, a finding with important implications for the ecology, long-term persistence, and evolution of the virus, including the potential for spillback to humans.
Journal ArticleDOI
Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy
Azizul Haque,Anudeep B. Pant +1 more
TL;DR: In this paper , the authors consider the conditions that may facilitate viral mutations and the emergence of variants with the ability to evade immunity and discuss the importance of vaccination with the currently available vaccines.
Journal ArticleDOI
Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study
TL;DR: In this article , an observational follow-up study included seven prospectively planned cohorts across six countries (Denmark, Estonia, Iceland, Norway, Sweden, and the UK). Participants were recruited from March 27, 2020, to Aug 13, 2021.
Journal ArticleDOI
COVID-19 vaccination and breakthrough infections in patients with cancer
TL;DR: In this paper , the authors describe the clinical features of patients with cancer who developed symptomatic COVID-19 following vaccination and compare weighted outcomes with those of contemporary unvaccinated patients, after adjustment for confounders.
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey,Clemens Sac.,Shabir A. Madhi,Lily Yin Weckx,P M Folegatti,Parvinder K. Aley,Brian Angus,Vicky L. Baillie,Shaun Barnabas,Q E Bhorat,S Bibi,Carmen Briner,P Cicconi,Andrea M. Collins,R Colin-Jones,Clare L. Cutland,Thomas C. Darton,Keertan Dheda,Duncan Cja.,Emary Krw.,Katie J. Ewer,Lee Fairlie,Saul N. Faust,Shuo Feng,Daniela M. Ferreira,Adam Finn,Anna Goodman,Catherine M. Green,Christopher A Green,Paul T. Heath,Christopher Hill,Helen Hill,Ian Hirsch,Hodgson Shc.,Allen Izu,S Jackson,D Jenkin,Joe Ccd.,S Kerridge,Anthonet Koen,Gaurav Kwatra,Rajeka Lazarus,Alison M. Lawrie,A Lelliott,Vincenzo Libri,Patrick J. Lillie,R Mallory,Mendes Ava.,Eveline Pipolo Milan,Angela M. Minassian,Alastair McGregor,Hazel Morrison,Y Mujadidi,Amit J Nana,P J O’Reilly,S D Padayachee,A Pittella,E Plested,Katrina M Pollock,M N Ramasamy,S Rhead,Alexandre Vargas Schwarzbold,Nisha Singh,Andrew Smith,R Song,Matthew D. Snape,Eduardo Sprinz,Rebecca K. Sutherland,R Tarrant,E. Thomson,M E Török,Mark Toshner,Turner Dpj.,Johan Vekemans,Tonya Villafana,Watson Mee.,C J Williams,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +81 more
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
TL;DR: The mRNA-1273 vaccine as discussed by the authors is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.
Journal ArticleDOI
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
Jamie Lopez Bernal,Nick Andrews,Charlotte Gower,Eileen Gallagher,Ruth Simmons,Simon Thelwall,Julia Stowe,Elise Tessier,Natalie Groves,Gavin Dabrera,Richard H. Myers,Colin Campbell,Gayatri Amirthalingam,Matt Edmunds,Maria Zambon,Kevin E. Brown,Susan Hopkins,Meera Chand,Mary Ramsay +18 more
TL;DR: The B.617.1.2 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus disease 2019 (Covid-19), has contributed to the development of the disease.
Journal ArticleDOI
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
Noa Dagan,Noam Barda,Noam Barda,Noam Barda,Eldad Kepten,Oren Miron,Oren Miron,Shay Perchik,Mark A. Katz,Mark A. Katz,Mark A. Katz,Miguel A. Hernán,Marc Lipsitch,Ben Y. Reis,Ran D. Balicer,Ran D. Balicer +15 more
TL;DR: This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
Related Papers (5)
The SARS‐CoV‐2 omicron wave is indicating the end of the pandemic phase but the COVID‐19 will continue
Sohel Daria,Rabiul Islam +1 more
Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - Mesa County, Colorado, April-June 2021.
COVID-19 rise in Bangladesh correlates with increasing detection of B.1.351 variant.
Senjuti Saha,Arif Mohammad Tanmoy,Yogesh Hooda,Afroza Akter Tanni,Sharmistha Goswami,Syed Muktadir Al Sium,Mohammad Saiful Islam Sajib,Roly Malaker,Shuborno Islam,Hafizur Rahman,Ataul Mustufa Anik,Nikkon Sarker,Mohammad Shariful Islam,Kinkar Ghosh,Probir Kumar Sarkar,Mohammed Rizwanul Ahsan Bipul,Syed Shafi Ahmed,Mohammod Shahidullah,Samir K. Saha +18 more